SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-21-000118
Filing Date
2021-01-29
Accepted
2021-01-28 20:30:12
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss191012_sc13da.htm SC 13D/A 69124
2 JOINT FILING AGREEMENT ss191012_ex9901.htm EX-99.1 5461
  Complete submission text file 0000947871-21-000118.txt   76121
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Subject) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91049 | Film No.: 21567486
SIC: 2836 Biological Products, (No Diagnostic Substances)